Featured Research

from universities, journals, and other organizations

Less than half of patients with MS continually adhere to drug therapies for treatment, Canadian study finds

Date:
May 10, 2011
Source:
St. Michael's Hospital
Summary:
Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new Canadian study, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis (MS), and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES), adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

Related Articles


"There are a number of reasons why adherence to therapies of proven value might be low," says Dr. Paul O'Connor, director of the MS Clinic at St. Michael's Hospital. "These drugs don't work in everyone and some patients may stop them because they don't feel they are experiencing benefits. In some cases, patients may stop treatment because of side-effects. It is important that patients understand the need for continuing treatment in order to prevent some of the long-term consequences of MS."

The study, published in the May edition of The Canadian Journal of Neurological Sciences, aimed to determine differential adherence to these drugs in Ontario given that they are each marketed as differential efficacy, side effects, or convenience.

The study found:

  • 682 Ontarians filling prescriptions through Ontario's Public Drug Programs were newly treated with a DMD for MS between April 2006 and March 2008
  • Although DMDs differ with respect to frequency of injection, costs and side-effect profiles, there is no indication that adherence to these medications varies substantially in Ontario
  • Despite their efficacy, adherence to all DMDs is low, with less than half of patients (44 per cent) continually adherent after 2 years.

"This study shows that adherence to treatment with DMDs is low, which is concerning given their proven effectiveness in slowing the progression of MS. We need to increase the appreciation of the long-term benefits of these medications to ensure that MS patients are receiving the best treatment available," says co-author Tara Gomes, an epidemiologist at ICES.

The use of these drug therapies for the treatment of MS has risen 30 per cent between 2002 and 2007, with associated costs rising from $187 to $287 million in Canada.


Story Source:

The above story is based on materials provided by St. Michael's Hospital. Note: Materials may be edited for content and length.


Cite This Page:

St. Michael's Hospital. "Less than half of patients with MS continually adhere to drug therapies for treatment, Canadian study finds." ScienceDaily. ScienceDaily, 10 May 2011. <www.sciencedaily.com/releases/2011/05/110510134104.htm>.
St. Michael's Hospital. (2011, May 10). Less than half of patients with MS continually adhere to drug therapies for treatment, Canadian study finds. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2011/05/110510134104.htm
St. Michael's Hospital. "Less than half of patients with MS continually adhere to drug therapies for treatment, Canadian study finds." ScienceDaily. www.sciencedaily.com/releases/2011/05/110510134104.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Newsy (Feb. 26, 2015) People who sleep more than eight hours per night are 45 percent more likely to have a stroke, according to a University of Cambridge study. Video provided by Newsy
Powered by NewsLook.com
London Show Dissects History of Forensic Science

London Show Dissects History of Forensic Science

AFP (Feb. 25, 2015) Forensic science, which has fascinated generations with its unravelling of gruesome crime mysteries, is being put under the microscope in an exhibition of real criminal investigations in London. Duration: 00:53 Video provided by AFP
Powered by NewsLook.com
Michigan Couple Celebrates Identical Triplets

Michigan Couple Celebrates Identical Triplets

AP (Feb. 25, 2015) A suburban Detroit couple who have two older children are adjusting to life after becoming parents to identical triplets _ a multiple birth a doctor calls rare. (Feb. 25) Video provided by AP
Powered by NewsLook.com
Mayor Says District of Columbia to Go Ahead With Pot Legalization

Mayor Says District of Columbia to Go Ahead With Pot Legalization

Reuters - News Video Online (Feb. 25, 2015) Washington&apos;s mayor says the District of Columbia will move forward with marijuana legalization, despite pushback from Congress. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins